Shogoo Pharmaceuticals K.K infectious news

Shogoo formed Shogoo Pharmaceuticals AG, a wholly owned subsidiary located in Basel, Switzerland. Rudolf Meyer, chairman of consulting firm InterPharmaLink AG, will be CEO of the subsidiary. The Swiss unit will have global rights to develop and commercialize SPK-0602, a broad-spectrum antimicrobial that is approved for vulvovaginitis in Switzerland and in preclinical testing for the indication in the EU. The parent company acquired rights to SPK-0602 from an undisclosed Swiss company. ...